Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Rhea-AI Summary

Abbott (NYSE: ABT) reported second-quarter 2026 sales of $12.6 billion, up 13.0% on a reported basis and 4.8% on a comparable basis. GAAP diluted EPS was $0.53 and adjusted diluted EPS was $1.31, excluding specified items. According to Abbott, the company reaffirmed full-year 2026 comparable sales growth guidance of 6.5%–7.5% and raised full-year adjusted EPS guidance to $5.45–$5.60 from $5.38–$5.58, and guided third-quarter adjusted EPS to $1.38–$1.46.

Diagnostics sales rose 42.3% reported (2.9% comparable), Medical Devices grew 9.0% reported (8.4% comparable), Established Pharmaceuticals grew 8.4% reported (8.7% comparable), while Nutrition declined 3.1% reported (3.6% comparable). Abbott returned $2.1 billion to shareholders via dividends and buybacks and declared its 410th consecutive quarterly dividend. The quarter also included completion of enrollment in the TECTONIC pivotal trial, CE Mark for Libre Duo, FDA submission for Amulet 360, and new data supporting pulsed field ablation and conduction system pacing portfolios.

Positive

• Q2 2026 sales $12.6B, up 13.0% reported and 4.8% comparable
• Adjusted Q2 EPS $1.31, with full-year 2026 guidance raised to $5.45–$5.60
• Diagnostics sales +42.3% reported; cancer diagnostics comparable growth 13.3%
• Medical Devices comparable sales +8.4%, led by electrophysiology and diabetes care
• Established Pharmaceuticals comparable sales +8.7%, key emerging markets +10.7%
• $2.1B returned to shareholders in Q2 via dividends and share repurchases

Negative

• Nutrition sales declined 3.1% reported and 3.6% comparable in Q2 2026
• Rapid and Molecular Diagnostics comparable sales declined 8.0% in Q2 2026
• Structural Heart and Neuromodulation posted low single-digit reported growth, below wider devices segment

News Explained

The disclosure adds a scheduled $0.63-per-share cash dividend, payable August 17, 2026, while comparable sales include Exact Sciences.

The July 16 results release reports Abbott’s second quarter and states that its March 23 acquisition of Exact Sciences was completed; its comparable-sales measure includes Exact Sciences’ sales in both the prior and current periods, so the reported growth figures incorporate that business rather than excluding it.

The board declared a $0.63-per-share quarterly cash dividend on June 12, payable August 17, 2026 to shareholders of record at the close of business on July 15, 2026.

News Market Reaction – ABT

+10.71% 2.3x vol

28 alerts

+10.71% News Effect

+9.7% Peak in 2 hr 10 min

+$15.04B Valuation Impact

$155.49B Market Cap

2.3x Rel. Volume

On the day this news was published, ABT gained 10.71%, reflecting a significant positive market reaction. Argus tracked a peak move of +9.7% during that session. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $15.04B to the company's valuation, bringing the market cap to $155.49B at that time. Trading volume was elevated at 2.3x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +10.7% in the session following this news. If a strong rally followed this report, ...

Analysis

The stock surged +10.7% in the session following this news. If a strong rally followed this report, it would fit with Abbott’s history of occasional outsized moves, such as the 3.04% gain on its June earnings-call notice. The raised EPS outlook contrasts with an active S-3ASR shelf and low short positioning, so dilution usage or sector sentiment shifts could still cap enthusiasm.

Key Figures

Total sales: $12,593M GAAP diluted EPS: $0.53 Adjusted diluted EPS: $1.31 +5 more

8 metrics

Total sales $12,593M 2Q26 reported company-wide revenue

GAAP diluted EPS $0.53 2Q26 earnings per share under GAAP

Adjusted diluted EPS $1.31 2Q26 EPS excluding specified items

Comparable sales growth 4.8% 2Q26 company-wide comparable sales growth

FY26 adj. EPS guidance $5.45–$5.60 Raised full-year 2026 adjusted diluted EPS range

Diagnostics sales growth 42.3% 2Q26 reported worldwide Diagnostics sales growth vs. 2Q25

Medical Devices sales growth 9.0% 2Q26 reported worldwide Medical Devices sales growth vs. 2Q25

Quarterly dividend $0.63 per share 410th consecutive quarterly dividend declared June 12, 2026

Historical Context

5 past events · Latest: Jun 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 25	Earnings call notice	Neutral	+3.0%	Scheduled timing and access details for upcoming second-quarter 2026 earnings call.
Jun 24	Licensing agreement	Positive	-0.0%	Global licensing deal to use ALZpath pTau217 antibody in Alzheimer’s blood testing.
Jun 22	Brand campaign news	Neutral	-0.2%	Similac survey and launch of “Love Without Measure” authenticity-focused parenting initiative.
Jun 12	Dividend declaration	Positive	-2.1%	410th consecutive quarterly dividend declaration with continued multi-decade dividend growth streak.
Jun 08	Clinical program data	Positive	+0.1%	New research results from Healthy Food Rx “Food is Medicine” program in type 2 diabetes.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent Abbott headlines have produced mixed single-day reactions, with several positive announcements met by flat or negative moves alongside roughly as many aligned responses.

Key Terms

pivotal trial, coronary intravascular lithotripsy, pulsed field ablation, conduction system pacing, +2 more

6 terms

pivotal trial medical

"completed enrollment in its TECTONIC U.S. pivotal trial."

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

coronary intravascular lithotripsy medical

"investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification"

A catheter-based heart procedure that uses low‑energy shock waves delivered through a balloon inside a blocked coronary artery to break up hard, calcified plaque so a stent or balloon can expand more easily. Think of it like using controlled sonic pulses to crack stubborn scale inside a pipe so repairs fit properly. It matters to investors because the technology, device sales, procedure volumes and hospital costs are tied to adoption and clinical outcomes in treating severe coronary artery disease.

pulsed field ablation medical

"data from four clinical trials that demonstrated strong clinical outcomes across the company's pulsed field ablation (PFA)"

Pulsed field ablation is a heart procedure that uses very short, high-voltage electrical pulses to selectively disrupt abnormal heart tissue that causes irregular rhythms, rather than heating or freezing it. For investors, it matters because this approach can shorten procedure times, reduce damage to nearby structures, and potentially lower complication rates compared with traditional thermal methods, which can affect device adoption, hospital costs, and market demand for treatment tools.

conduction system pacing medical

"strong clinical outcomes across the company's pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios."

A heart-rhythm treatment where a pacemaker lead is placed to directly stimulate the heart’s natural electrical wiring so each beat follows the heart’s own pathway, producing a more natural and coordinated contraction—think of fixing a traffic signal at its source instead of directing cars from the side. It matters to investors because better outcomes and fewer complications can change demand for specific devices, shift hospital purchasing and reimbursement patterns, and influence which manufacturers and technologies gain market share.

ce mark regulatory

"Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone"

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

left atrial appendage medical

"Amulet™ 360 left atrial appendage (LAA) device."

The left atrial appendage is a small, pouch-like outcrop on the left upper chamber of the heart that can trap blood clots, especially when the heart beats irregularly. For investors, it matters because treatments that close, remove, or influence clot formation in this pouch — either with devices, procedures, or drugs — can drive demand, regulatory review, reimbursement decisions, and clinical trial outcomes tied to related medical products and services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent
• Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31
• Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%¹
• Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58
• Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchases

ABBOTT PARK, Ill., July 16, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2026.

• Second-quarter sales increased 13.0 percent on a reported basis and 4.8 percent on a comparable basis.
• Second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items.
• Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%¹.
• Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58.
• In April, Abbott completed enrollment in its TECTONIC U.S. pivotal trial. This trial is designed to evaluate Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification in coronary arteries prior to stent implantation.
• In April, at the Heart Rhythm Society (HRS) conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company's pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios.
• In May, Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.
• In May, Abbott completed its submission to the U.S. Food and Drug Administration (FDA) seeking approval for the company's Amulet™ 360 left atrial appendage (LAA) device.
• In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard® and Cologuard Plus® as preferred screening options for adults age 45 and older who are at average risk for CRC.

"Our second-quarter results reflect the momentum we are building," said Robert B. Ford, chairman and chief executive officer, Abbott. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."

SECOND-QUARTER BUSINESS OVERVIEW

Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. 

Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)	Total Company		Nutrition		Diagnostics		Established Pharmaceuticals		Medical Devices
U.S.	5,216		871		1,660		—		2,680
International	7,377		1,273		1,432		1,499		3,173
Total reported	12,593		2,144		3,092		1,499		5,853
% Change vs. 2Q25
U.S.	22.0		(9.0)		104.8		n/a		7.0
International	7.5		1.4		5.1		8.4		10.7
Total reported	13.0		(3.1)		42.3		8.4		9.0
Total reported excl. foreign exchange impact	12.2		(3.6)		41.3		8.7		7.9
Comparable sales growth	4.8		(3.6)		2.9		8.7		8.4
U.S.	3.5		(9.0)		4.0		n/a		8.0
International	5.8		0.6		1.6		8.7		8.7

 

First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)	Total Company		Nutrition		Diagnostics		Established Pharmaceuticals		Medical Devices
U.S.	9,490		1,715		2,565		—		5,203
International	14,267		2,446		2,707		2,925		6,189
Total reported	23,757		4,161		5,272		2,925		11,392
% Change vs. 1H25
U.S.	12.4		(10.3)		52.5		n/a		7.4
International	9.3		—		6.4		10.7		14.2
Total reported	10.5		(4.5)		24.7		10.7		11.0
Total reported excl. foreign exchange impact	8.2		(5.6)		22.4		8.9		8.0
Comparable sales growth	4.3		(5.6)		2.4		8.9		8.4
U.S.	3.0		(10.3)		3.0		n/a		8.3
International	5.3		(1.9)		1.6		8.9		8.5

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

 

Nutrition
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)	Total		Pediatric		Adult
U.S.	871		525		346
International	1,273		500		773
Total reported	2,144		1,025		1,119
% Change vs. 2Q25
U.S.	(9.0)		(10.7)		(6.4)
International	1.4		7.3		(2.0)
Total reported	(3.1)		(2.7)		(3.4)
Total reported excl. foreign exchange impact	(3.6)		(3.1)		(4.0)
Comparable sales growth	(3.6)		(3.1)		(4.0)
U.S.	(9.0)		(10.7)		(6.4)
International	0.6		6.4		(2.8)

Worldwide Nutrition sales decreased 3.1 percent on a reported basis and 3.6 percent on a comparable basis in the second quarter.

Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of new products, are contributing to improving performance. Nutrition sales increased $127 million on a sequential basis compared to the first quarter of 2026. 

First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)	Total		Pediatric		Adult
U.S.	1,715		1,036		679
International	2,446		942		1,504
Total reported	4,161		1,978		2,183
% Change vs. 1H25
U.S.	(10.3)		(11.9)		(7.8)
International	—		2.4		(1.5)
Total reported	(4.5)		(5.6)		(3.5)
Total reported excl. foreign exchange impact	(5.6)		(6.4)		(4.9)
Comparable sales growth	(5.6)		(6.4)		(4.9)
U.S.	(10.3)		(11.9)		(7.8)
International	(1.9)		0.7		(3.5)

 

Diagnostics*
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)	Total		Core Laboratory		Cancer Diagnostics		Rapid/Molecular Diagnostics
U.S.	1,660		377		890		393
International	1,432		1,041		29		362
Total reported	3,092		1,418		919		755
% Change vs. 2Q25
U.S.	104.8		7.5		n/a		(14.5)
International	5.1		3.4		n/a		2.0
Total reported	42.3		4.4		n/a		(7.3)
Total reported excl. foreign exchange impact	41.3		3.2		n/a		(8.0)
Comparable sales growth	2.9		3.2		13.3		(8.0)
U.S.	4.0		7.5		13.3		(14.5)
International	1.6		1.7		13.8		0.5

Worldwide Diagnostics sales increased 42.3 percent on a reported basis and 2.9 percent on a comparable basis in the second quarter.

Worldwide Core Laboratory Diagnostics results were driven by strong growth in the U.S. and Latin America.

Rapid and Molecular Diagnostics results reflect lower sales of respiratory virus tests compared to the prior year.

Cancer Diagnostics results were driven by mid-teens growth of Cologuard, which is benefiting from a growing base of both new and repeat users. Results in the quarter also reflect contributions to growth from the precision oncology and international businesses. 

First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)	Total		Core Laboratory		Cancer Diagnostics		Rapid/Molecular Diagnostics
U.S.	2,565		724		983		858
International	2,707		1,966		32		709
Total reported	5,272		2,690		1,015		1,567
% Change vs. 1H25
U.S.	52.5		6.0		n/a		(14.1)
International	6.4		6.1		n/a		2.4
Total reported	24.7		6.1		n/a		(7.4)
Total reported excl. foreign exchange impact	22.4		3.2		n/a		(8.8)
Comparable sales growth	2.4		3.2		13.3		(8.8)
U.S.	3.0		6.0		13.2		(14.1)
International	1.6		2.2		16.5		(1.1)

*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

 

Established Pharmaceuticals
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)	Total		Key Emerging Markets		Other
U.S.	—		—		—
International	1,499		1,164		335
Total reported	1,499		1,164		335
% Change vs. 2Q25
U.S.	n/a		n/a		n/a
International	8.4		9.8		3.7
Total reported	8.4		9.8		3.7
Total reported excl. foreign exchange impact	8.7		10.7		2.1
Comparable sales growth	8.7		10.7		2.1
U.S.	n/a		n/a		n/a
International	8.7		10.7		2.1

Established Pharmaceuticals sales increased 8.4 percent on a reported basis and 8.7 percent on a comparable basis in the second quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.8 percent on a reported basis and 10.7 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions. 

First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)	Total		Key Emerging Markets		Other
U.S.	—		—		—
International	2,925		2,253		672
Total reported	2,925		2,253		672
% Change vs. 1H25
U.S.	n/a		n/a		n/a
International	10.7		11.3		8.6
Total reported	10.7		11.3		8.6
Total reported excl. foreign exchange impact	8.9		10.1		4.9
Comparable sales growth	8.9		10.1		4.9
U.S.	n/a		n/a		n/a
International	8.9		10.1		4.9

 

Medical Devices
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)	Total		Rhythm Management		Electro- physiology*		Heart Failure		Vascular		Structural Heart*		Neuro- modulation		Diabetes Care
U.S.	2,680		377		420		313		294		225		189		862
International	3,173		366		441		88		509		372		71		1,326
Total reported	5,853		743		861		401		803		597		260		2,188
% Change vs. 2Q25
U.S.	7.0		10.7		15.9		10.9		3.9		(9.8)		(2.1)		8.6
International	10.7		10.0		12.3		3.0		7.5		12.1		14.7		11.7
Total reported	9.0		10.4		14.0		9.0		6.1		2.7		2.0		10.5
Total reported excl. foreign exchange impact	7.9		9.5		13.4		8.7		5.1		1.7		1.2		9.0
Comparable sales growth	8.4		9.5		13.4		8.7		5.1		5.7		1.2		9.0
U.S.	8.0		10.7		15.9		10.9		3.9		(0.9)		(2.1)		8.6
International	8.7		8.3		11.1		1.3		5.8		10.2		11.3		9.2

Worldwide Medical Devices sales increased 9.0 percent on a reported basis and 8.4 percent on a comparable basis in the second quarter.

Sales growth in the quarter was led by low-teens growth in Electrophysiology and high-single-digit growth in Rhythm Management, Diabetes Care, and Heart Failure.

In Diabetes Care, sales of continuous glucose monitors grew 11.0 percent on a reported basis and 9.5 percent on a comparable basis. 

First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)	Total		Rhythm Management		Electro- physiology*		Heart Failure		Vascular		Structural Heart*		Neuro- modulation		Diabetes Care
U.S.	5,203		716		798		605		585		449		366		1,684
International	6,189		711		851		185		995		726		137		2,584
Total reported	11,392		1,427		1,649		790		1,580		1,175		503		4,268
% Change vs. 1H25
U.S.	7.4		11.1		14.8		11.1		6.2		(9.6)		(0.7)		9.2
International	14.2		15.9		15.7		13.5		8.7		18.1		20.4		14.0
Total reported	11.0		13.4		15.3		11.7		7.7		5.7		4.3		12.1
Total reported excl. foreign exchange impact	8.0		10.9		13.0		10.4		5.0		2.6		2.6		8.2
Comparable sales growth	8.4		10.9		13.0		10.4		5.0		6.2		2.6		8.2
U.S.	8.3		11.1		14.8		11.1		6.2		(2.2)		(0.7)		9.2
International	8.5		10.7		11.2		7.8		4.3		12.4		13.2		7.5

*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 and $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%¹.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.45 to $5.60.

Abbott projects third-quarter 2026 adjusted diluted earnings per share of $1.38 to $1.46.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

Abbott Declares 410^th Consecutive Quarterly Dividend
On June 12, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. 

Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

1. In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott's Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million.

Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings Second Quarter Ended June 30, 2026 and 2025 (in millions, except per share data) (unaudited)
	2Q26		2Q25		% Change
Net Sales	$12,593		$11,142		13.0
Cost of products sold, excluding amortization expense	5,325		4,854		9.7
Amortization of intangible assets	658		420		56.8
Research and development	892		725		22.9
Selling, general, and administrative	4,025		3,091		30.3
Total Operating Cost and Expenses	10,900		9,090		19.9
Operating Earnings	1,693		2,052		(17.5)
Interest expense, net	299		50		n/m
Net foreign exchange (gain) loss	4		(11)		n/m
Other (income) expense, net	(134)		(137)		(2.5)
Earnings before taxes	1,524		2,150		(29.1)
Taxes on Earnings	596		371		60.8	1)
Net Earnings	$928		$1,779		(47.8)
Net Earnings excluding Specified Items, as described below	$2,290		$2,213		3.5	2)
Diluted Earnings per Common Share	$0.53		$1.01		n/m
Diluted Earnings per Common Share, excluding Specified Items, as described below	$1.31		$1.26		4.0	2)
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,743		1,751

NOTES:
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following section.
1)	2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
	2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)	2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.362 billion, or $0.78 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, and other net expenses.
	2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $434 million, or $0.25 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.

 

Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings First Half Ended June 30, 2026 and 2025 (in millions, except per share data) (unaudited)
	1H26		1H25		% Change
Net Sales	$23,757		$21,500		10.5
Cost of products sold, excluding amortization expense	10,215		9,322		9.6
Amortization of intangible assets	1,080		840		28.5
Research and development	1,659		1,441		15.1
Selling, general, and administrative	7,765		6,152		26.2
Total Operating Cost and Expenses	20,719		17,755		16.7
Operating Earnings	3,038		3,745		(18.9)
Interest expense, net	367		99		n/m
Net foreign exchange (gain) loss	(9)		(18)		n/m
Other (income) expense, net	(293)		(264)		10.6
Earnings before taxes	2,973		3,928		(24.3)
Taxes on earnings	968		824		17.5	1)
Net Earnings	$2,005		$3,104		n/m
Net Earnings excluding Specified Items, as described below	$4,312		$4,132		4.4	2)
Diluted Earnings per Common Share	$1.14		$1.77		n/m
Diluted Earnings per Common Share, excluding Specified Items, as described below	$2.46		$2.35		4.7	2)
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,745		1,749

NOTES:
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following section.
1)	2026 Taxes on Earnings includes the recognition of approximately $60 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
	2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)	2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $2.307 billion, or $1.32 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, restructuring, and other net expenses.
	2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.028 billion, or $0.58 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

 

Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information Second Quarter Ended June 30, 2026 and 2025 (in millions, except per share data) (unaudited)
	2Q26
	As Reported (GAAP)		Specified Items		As Adjusted
Intangible Amortization	$      658		$     (658)		$        —
Gross Margin	6,610		697		7,307
R&D	892		(25)		867
SG&A	4,025		(428)		3,597
Other (income) expense, net	(134)		(27)		(161)
Earnings before taxes	1,524		1,177		2,701
Taxes on Earnings	596		(185)		411
Net Earnings	928		1,362		2,290
Diluted Earnings per Share	$     0.53		$      0.78		$      1.31

Specified items reflect intangible amortization expense of $658 million and other net expenses of $519 million associated with acquisitions, legal reserves, investment impairments, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

	2Q25
	As Reported (GAAP)		Specified Items		As Adjusted
Intangible Amortization	$      420		$     (420)		$        —
Gross Margin	5,868		478		6,346
R&D	725		(20)		705
SG&A	3,091		(1)		3,090
Other (income) expense, net	(137)		(1)		(138)
Earnings before taxes	2,150		500		2,650
Taxes on Earnings	371		66		437
Net Earnings	1,779		434		2,213
Diluted Earnings per Share	$      1.01		$      0.25		$      1.26

Specified items reflect intangible amortization expense of $420 million and other net expenses of $80 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information First Half Ended June 30, 2026 and 2025 (in millions, except per share data) (unaudited)
	1H26
	As Reported (GAAP)		Specified Items		As Adjusted
Intangible Amortization	$    1,080		$   (1,080)		$        —
Gross Margin	12,462		1,129		13,591
R&D	1,659		(49)		1,610
SG&A	7,765		(901)		6,864
Other (income) expense, net	(293)		(34)		(327)
Earnings before taxes	2,973		2,113		5,086
Taxes on Earnings	968		(194)		774
Net Earnings	2,005		2,307		4,312
Diluted Earnings per Share	$      1.14		$      1.32		$     2.46

Specified items reflect intangible amortization expense of $1.080 billion and other net expenses of $1.033 billion associated with restructuring actions, acquisitions, legal reserves, investment impairments, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

	1H25
	As Reported (GAAP)		Specified Items		As Adjusted
Intangible Amortization	$      840		$     (840)		$        —
Gross Margin	11,338		926		12,264
R&D	1,441		(47)		1,394
SG&A	6,152		(11)		6,141
Other (income) expense, net	(264)		(36)		(300)
Earnings before taxes	3,928		1,020		4,948
Taxes on Earnings	824		(8)		816
Net Earnings	3,104		1,028		4,132
Diluted Earnings per Share	$      1.77		$      0.58		$     2.35

Specified items reflect intangible amortization expense of $840 million and other net expenses of $180 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

A reconciliation of the second-quarter tax rates for 2026 and 2025 is shown below: 

	2Q26
($ in millions)	Pre-Tax Income		Taxes on Earnings		Tax Rate
As reported (GAAP)	$    1,524		$      596		39.1 %	1)
Specified items	1,177		(185)
Excluding specified items	$    2,701		$       411		15.2 %
	2Q25
($ in millions)	Pre-Tax Income		Taxes on Earnings		Tax Rate
As reported (GAAP)	$    2,150		$       371		17.3 %	2)
Specified items	500		66
Excluding specified items	$    2,650		$      437		16.5 %

1)	2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)	2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below: 

	1H26
($ in millions)	Pre-Tax Income		Taxes on Earnings		Tax Rate
As reported (GAAP)	$    2,973		$      968		32.5 %	3)
Specified items	2,113		(194)
Excluding specified items	$    5,086		$      774		15.2 %
	1H25
($ in millions)	Pre-Tax Income		Taxes on Earnings		Tax Rate
As reported (GAAP)	$    3,928		$      824		21.0 %	4)
Specified items	1,020		(8)
Excluding specified items	$   4,948		$      816		16.5 %

3)	2026 Taxes on Earnings includes the recognition of approximately $60 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
4)	2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

 

Abbott Laboratories and Subsidiaries Non-GAAP Revenue Reconciliation Second Quarter Ended June 30, 2026 and 2025 ($ in millions) (unaudited)
	2Q26				2Q25					% Change vs. 2Q25
											Non-GAAP
	Abbott Reported	Foreign exchange	Comparable Revenue		Abbott Reported	Impact of acquisition (a)	Impact of multi-year agreement (b)	Comparable Revenue		Reported	Comparable
Total Company	12,593	(86)	12,507		11,142	811	(22)	11,931		13.0	4.8
U.S.	5,216	—	5,216		4,276	786	(22)	5,040		22.0	3.5
Intl	7,377	(86)	7,291		6,866	25	—	6,891		7.5	5.8
Total Diagnostics	3,092	(22)	3,070		2,173	811	—	2,984		42.3	2.9
U.S.	1,660	—	1,660		811	786	—	1,597		104.8	4.0
Intl	1,432	(22)	1,410		1,362	25	—	1,387		5.1	1.6
Total Cancer Diagnostics	919	—	919		—	811	—	811		n/a	13.3
U.S.	890	—	890		—	786	—	786		n/a	13.3
Intl	29	—	29		—	25	—	25		n/a	13.8
Total Medical Devices	5,853	(57)	5,796		5,369	—	(22)	5,347		9.0	8.4
U.S.	2,680	—	2,680		2,503	—	(22)	2,481		7.0	8.0
Intl	3,173	(57)	3,116		2,866	—	—	2,866		10.7	8.7
Total Structural Heart*	597	(6)	591		581	—	(22)	559		2.7	5.7
U.S.	225	—	225		249	—	(22)	227		(9.8)	(0.9)
Intl	372	(6)	366		332	—	—	332		12.1	10.2

*	Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 were moved from Structural Heart to Electrophysiology.
a)	The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.
b)	Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

 

Abbott Laboratories and Subsidiaries Non-GAAP Revenue Reconciliation First Half Ended June 30, 2026 and 2025 ($ in millions) (unaudited)
	1H26						1H25					% Change vs. 1H25
													Non-GAAP
	Abbott Reported	Impact of acquisition (a)	Impact of multi-year agreement (b)	Foreign exchange	Comparable Revenue		Abbott Reported	Impact of acquisition (a)	Impact of multi-year agreement (b)	Comparable Revenue		Reported	Comparable
Total Company	23,757	706	(8)	(500)	23,955		21,500	1,518	(46)	22,972		10.5	4.3
U.S.	9,490	681	(8)	—	10,163		8,444	1,470	(46)	9,868		12.4	3.0
Intl	14,267	25	—	(500)	13,792		13,056	48	—	13,104		9.3	5.3
Total Diagnostics	5,272	706	—	(98)	5,880		4,227	1,518	—	5,745		24.7	2.4
U.S.	2,565	681	—	—	3,246		1,682	1,470	—	3,152		52.5	3.0
Intl	2,707	25	—	(98)	2,634		2,545	48	—	2,593		6.4	1.6
Total Cancer Diagnostics	1,015	706	—	(1)	1,720		—	1,518	—	1,518		n/a	13.3
U.S.	983	681	—	—	1,664		—	1,470	—	1,470		n/a	13.2
Intl	32	25	—	(1)	56		—	48	—	48		n/a	16.5
Total Medical Devices	11,392	—	(8)	(306)	11,078		10,264	—	(46)	10,218		11.0	8.4
U.S.	5,203	—	(8)	—	5,195		4,842	—	(46)	4,796		7.4	8.3
Intl	6,189	—	—	(306)	5,883		5,422	—	—	5,422		14.2	8.5
Total Structural Heart*	1,175	—	(8)	(35)	1,132		1,112	—	(46)	1,066		5.7	6.2
U.S.	449	—	(8)	—	441		497	—	(46)	451		(9.6)	(2.2)
Intl	726	—	—	(35)	691		615	—	—	615		18.1	12.4

*	Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.
a)	The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.
b)	Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

 

Abbott Laboratories and Subsidiaries Details of Specified Items Second Quarter Ended June 30, 2026 (in millions, except per share data) (unaudited)
	Acquisition or Divestiture- related (a)		Restructuring and Cost Reduction Initiatives (b)		Intangible Amortization		Other (c)		Total Specifieds
Gross Margin	$           32		$               4		$         658		$            3		$         697
R&D	(10)		—		—		(15)		(25)
SG&A	(42)		(1)		—		(385)		(428)
Other (income) expense, net	1		(1)		—		(27)		(27)
Earnings before taxes	$           83		$               6		$         658		$         430		1,177
Taxes on Earnings (d)									(185)
Net Earnings									$        1,362
Diluted Earnings per Share									$        0.78

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)	Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.
b)	Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.
c)	Other includes $385 million for legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies, as well as charges related to investment impairments and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)	Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

 

Abbott Laboratories and Subsidiaries Details of Specified Items Second Quarter Ended June 30, 2025 (in millions, except per share data) (unaudited)
	Acquisition or  Divestiture- related (a)		Restructuring and Cost Reduction Initiatives (b)		Intangible Amortization		Other (c)		Total Specifieds
Gross Margin	$             1		$             55		$         420		$            2		$         478
R&D	—		(7)		—		(13)		(20)
SG&A	(3)		1		—		1		(1)
Other (income) expense, net	(1)		—		—		—		(1)
Earnings before taxes	$            5		$              61		$         420		$           14		500
Taxes on Earnings (d)									66
Net Earnings									$         434
Diluted Earnings per Share									$        0.25

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)	Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.
b)	Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)	Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)	Reflects the net tax benefit associated with the specified items and the recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

 

Abbott Laboratories and Subsidiaries Details of Specified Items First Half Ended June 30, 2026 (in millions, except per share data) (unaudited)
	Acquisition or Divestiture- related (a)		Restructuring and Cost Reduction Initiatives (b)		Intangible Amortization		Other (c)		Total Specifieds
Gross Margin	$           34		$               11		$       1,080		$            4		$        1,129
R&D	(11)		(10)		—		(28)		(49)
SG&A	(486)		(34)		—		(381)		(901)
Other (income) expense, net	(1)		(3)		—		(30)		(34)
Earnings before taxes	$         532		$             58		$       1,080		$         443		2,113
Taxes on Earnings (d)									(194)
Net Earnings									$       2,307
Diluted Earnings per Share									$         1.32

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)	Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.
b)	Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.
c)	Other includes $385 million for legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies, as well as charges related to investment impairments and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)	Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

 

Abbott Laboratories and Subsidiaries Details of Specified Items First Half Ended June 30, 2025 (in millions, except per share data) (unaudited)
	Acquisition or Divestiture- related (a)		Restructuring and Cost Reduction Initiatives (b)		Intangible Amortization		Other (c)		Total Specifieds
Gross Margin	$             1		$              81		$         840		$            4		$         926
R&D	(1)		(23)		—		(23)		(47)
SG&A	(6)		(6)		—		1		(11)
Other (income) expense, net	(25)		—		—		(11)		(36)
Earnings before taxes	$           33		$             110		$         840		$           37		1,020
Taxes on Earnings (d)									(8)
Net Earnings									$       1,028
Diluted Earnings per Share									$        0.58

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)	Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)	Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)	Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.
d)	Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

 

View original content:https://www.prnewswire.com/news-releases/abbott-reports-second-quarter-2026-results-and-raises-full-year-eps-guidance-302827508.html

SOURCE Abbott

FAQ

How did Abbott (ABT) perform in the second quarter of 2026?

Abbott reported Q2 2026 sales of $12.6 billion, up 13.0% reported and 4.8% comparable. According to Abbott, GAAP diluted EPS was $0.53 and adjusted diluted EPS was $1.31, reflecting contributions from diagnostics, medical devices, and established pharmaceuticals.

What EPS guidance did Abbott (ABT) give for full-year 2026?

Abbott raised its full-year 2026 adjusted diluted EPS guidance to $5.45–$5.60. According to Abbott, this compares with its previous range of $5.38–$5.58 and is based on projected comparable sales growth of 6.5%–7.5% for the year.

How did Abbott’s main business segments perform in Q2 2026?

In Q2 2026, diagnostics sales grew 42.3% reported, medical devices grew 9.0%, and established pharmaceuticals grew 8.4%. According to Abbott, nutrition sales declined 3.1% reported, reflecting lower volumes and prior strategic pricing actions but improved sequential performance.

What guidance did Abbott (ABT) provide for third-quarter 2026 EPS?

Abbott projected third-quarter 2026 adjusted diluted EPS of $1.38–$1.46. According to Abbott, related GAAP EPS guidance was not provided because items like restructuring, acquisition costs, and foreign exchange effects cannot be reasonably estimated in advance without unreasonable effort.

How much capital did Abbott return to shareholders in Q2 2026?

Abbott returned $2.1 billion to shareholders in Q2 2026 through dividends and share repurchases. According to Abbott, its board also declared the company’s 410th consecutive quarterly dividend on June 12, 2026, continuing a long-running capital return track record.

What were the key clinical and regulatory milestones for Abbott in Q2 2026?

Key milestones included CE Mark for Libre Duo, FDA submission for Amulet 360, and completion of enrollment in the TECTONIC trial. According to Abbott, new Heart Rhythm Society data supported its pulsed field ablation and conduction system pacing portfolios.

How is Abbott’s acquisition of Exact Sciences reflected in 2026 results?

According to Abbott, comparable sales growth includes prior and current year sales of Exact Sciences, acquired March 23, 2026. Following the acquisition, Exact Sciences’ sales are reported as Abbott’s Cancer Diagnostics business, contributing to mid-teens Cologuard growth and broader oncology performance.